控制药品和生物制品价格的商业排他性个性化时期

American journal of immunology Pub Date : 2019-01-01 DOI:10.3844/AJISP.2019.19.21

Callie M. Blase, Brandon K. Rouault, Maia B. Zoller, Joshua V. Luff, Emma J. Lerch, Brynn N. Lauterbachq, Mark A. Brown, J. Storsberg, C. Schmidt

{"title":"控制药品和生物制品价格的商业排他性个性化时期","authors":"Callie M. Blase, Brandon K. Rouault, Maia B. Zoller, Joshua V. Luff, Emma J. Lerch, Brynn N. Lauterbachq, Mark A. Brown, J. Storsberg, C. Schmidt","doi":"10.3844/AJISP.2019.19.21","DOIUrl":null,"url":null,"abstract":"The pricing for immunologic agents and antibody-based therapeutics has increased precipitously in recent years. Among the key contributors to price hikes is the static practice of granting commercial exclusivity to innovator drugs and biologics. Herein, we present a mechanism for individualizing periods of commercial exclusivity to control pricing for drugs and biologics.","PeriodicalId":88361,"journal":{"name":"American journal of immunology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Individualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and Biologics\",\"authors\":\"Callie M. Blase, Brandon K. Rouault, Maia B. Zoller, Joshua V. Luff, Emma J. Lerch, Brynn N. Lauterbachq, Mark A. Brown, J. Storsberg, C. Schmidt\",\"doi\":\"10.3844/AJISP.2019.19.21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The pricing for immunologic agents and antibody-based therapeutics has increased precipitously in recent years. Among the key contributors to price hikes is the static practice of granting commercial exclusivity to innovator drugs and biologics. Herein, we present a mechanism for individualizing periods of commercial exclusivity to control pricing for drugs and biologics.\",\"PeriodicalId\":88361,\"journal\":{\"name\":\"American journal of immunology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3844/AJISP.2019.19.21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3844/AJISP.2019.19.21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

近年来，免疫制剂和基于抗体的治疗方法的价格急剧上涨。价格上涨的主要原因之一是给予创新药物和生物制品商业排他性的静态做法。在此，我们提出了一种商业排他性时期的个性化机制，以控制药物和生物制品的定价。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Individualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and Biologics

The pricing for immunologic agents and antibody-based therapeutics has increased precipitously in recent years. Among the key contributors to price hikes is the static practice of granting commercial exclusivity to innovator drugs and biologics. Herein, we present a mechanism for individualizing periods of commercial exclusivity to control pricing for drugs and biologics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American journal of immunology

自引率

0.00%

发文量